Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
A new high-resolution structural study of Armata’s Ar-KM bacteriophage deepens mechanistic insight that may inform future phage therapeutic development.
Rhea-AI Summary
Armata Pharmaceuticals (ARMP) announced publication of a peer-reviewed paper in the Journal of Molecular Biology that provides an integrative structural atlas of Ar-KM, a therapeutic phiKMV-like bacteriophage targeting Pseudomonas aeruginosa, the pathogen addressed by Armata’s inhaled phage candidate AP-PA02.
The study uses cryo-electron microscopy, proteomics and bioinformatics to capture three distinct structural states of Ar-KM from a single purified preparation and to build atomic models for eleven structural proteins at near-atomic resolution. The work explains how Ar-KM keeps its genome securely packaged before infection, identifies an enzyme activity that helps the phage penetrate the bacterial cell envelope, and characterizes a previously unrecognized protein involved in coordinated genome release and delivery. Armata highlights that these insights link fundamental phage biology to properties important for therapeutic development, such as stability, infectivity and efficient genome delivery, and are supported by its proprietary phage purification processes.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Q2 earnings report | Positive | +11.8% | Corporate progress, funding, and regulatory milestones accompanied the quarterly results. |
| Jul 20 | Phase 3 progress | Positive | +12.2% | Phase 3 preparation, manufacturing progress, and additional non-dilutive funding were reported. |
| Jul 13 | Pediatric plan agreement | Positive | -6.8% | FDA agreement on the Initial Pediatric Study Plan advanced AP-SA02 development. |
| Jun 23 | DoD funding | Positive | +2.0% | Additional non-dilutive funding increased total support for AP-SA02. |
| May 13 | Q1 earnings report | Negative | -7.0% | Higher expenses and substantially increased net loss accompanied the corporate update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operational and funding announcements generally aligned with gains, while the July 13 regulatory update diverged with a decline.
Key Terms
bacteriophage medical
cryo-electron microscopy technical
proteomics technical
bioinformatics technical
mass spectrometry technical
cGMP regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The publication, titled "Insights into Genome Ejection by a Therapeutic phiKMV-like Bacteriophage," presents an integrative structural atlas of Ar-KM, a phiKMV-like bacteriophage that targets Pseudomonas aeruginosa ("P. aeruginosa"), the pathogen addressed by Armata's AP-PA02 program. AP-PA02 is an inhaled bacteriophage product candidate that has completed Phase 2 clinical studies in both cystic fibrosis ("CF") and non-CF bronchiectasis ("NCFB") patients with chronic pulmonary P. aeruginosa infection. Using cryo-electron microscopy, proteomics, and bioinformatics, the researchers captured three distinct states of the phage particle from a single purified preparation and built atomic models for eleven structural proteins at near-atomic resolution. The work explains how Ar-KM keeps its genome securely packaged before infection, identifies an enzyme activity that helps the phage penetrate the bacterial cell envelope, and characterizes a previously unrecognized protein that enables the coordinated release and delivery of the genome into the bacterium.
"Stability before infection and efficient genome delivery at the point of infection are fundamental characteristics of a viable phage therapeutic, and this work provides important new insight into how Ar-KM can achieve both," said Dr. Deborah Birx, Chief Executive Officer of Armata, and co-author of the paper. "More broadly, our collaboration with Dr. Cingolani's group is helping us build a deeper understanding of the structural biology and mechanisms that underpin phage activity and can inform the rational development of our anti-infective pipeline. This marks the fourth publication from our collaboration and the fourth characterizing our Pseudomonas aeruginosa phages, and we are now extending this work to cryo-EM reconstruction of our proprietary Staphylococcus aureus phages. The exceptional resolution achieved in these studies is also supported by our proprietary purification processes, which enable the high quality pure phage preparations required for high-resolution structural analysis. We believe applying these capabilities across our portfolio can strengthen our understanding of phage mechanism of action and support the development of differentiated therapies targeting difficult-to-treat pathogens."
Dr. Gino Cingolani, Anderson Family Endowed Chair in Medical Education, Research & Patient Care, and Professor in the Department of Biochemistry and Molecular Genetics, The University of
Dr. Cingolani added, "Together, these findings provide a clearer understanding of how Ar-KM remains stable until it reaches its target and then efficiently transitions into infection mode. These insights also help connect the fundamental biology of the phage with characteristics important to the development of effective phage therapies, including stability, infectivity and efficient genome delivery."
The full paper (J Mol Biol. 2026 Nov 1; 438(21):169993) can be found here.
About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.
Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-new-publication-that-advances-understanding-of-phage-biology-to-support-development-of-next-generation-antibacterials-302868362.html
SOURCE Armata Pharmaceuticals, Inc.